Treatment of myopathy and cutaneous ulcers in anti-MDA5-positive dermatomyositis with triple therapy.
| Autor: | Peringeth G; Department of Medicine, Albert Einstein College of Medicine, Bronx, New York, USA gperingeth@montefiore.org., Abbi B; Department of Medicine, Albert Einstein College of Medicine, Bronx, New York, USA.; Rheumatology, Lahey Hospital and Medical Center, Burlington, Massachusetts, USA., Mahmood S; Department of Medicine, Albert Einstein College of Medicine, Bronx, New York, USA. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | BMJ case reports [BMJ Case Rep] 2024 Mar 21; Vol. 17 (3). Date of Electronic Publication: 2024 Mar 21. |
| DOI: | 10.1136/bcr-2022-253960 |
| Abstrakt: | Antimelanoma differentiation-associated protein 5 positive dermatomyositis (MDA5 DM) is a rare subtype of idiopathic inflammatory myopathy. There are limited data available regarding the cutaneous manifestations of MDA5 DM in the African American population. We presented the case of a male patient in his early 20s who presented with debilitating cutaneous ulceration and myopathy. Workup revealed interstitial lung disease (ILD) and positive MDA5 serology consistent with MDA5 DM. He made a remarkable recovery in terms of myopathy and cutaneous ulcerations with a multipronged regimen of prednisone, intravenous immunoglobulin and mycophenolate mofetil. However, there was a progression of ILD on this regimen which warranted use of rituximab. Competing Interests: Competing interests: None declared. (© BMJ Publishing Group Limited 2024. No commercial re-use. See rights and permissions. Published by BMJ.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|